[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507310":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":44,"collaborators":46,"id":49,"slug":7,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":7,"studyType":63,"phases":7,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Katharina Timper, Prof.","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+41613285742","katharina.timper@usb.ch",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Valerie Mettraux","+41613285520","valerie.mettraux@usb.ch",[22],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland",{"type":29,"coordinates":30},"Point",[31,32],7.57327,47.55839,{"lat":32,"lon":31},[35,37,39,40,42],{"name":10,"role":14,"phone":36,"phoneExt":7,"email":16},"+4161 328 57 42",{"name":18,"role":14,"phone":38,"phoneExt":7,"email":20},"+4161 328 55 20",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":18,"role":41,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":43,"role":41,"phone":7,"phoneExt":7,"email":7},"Lolita Matiashova, Dr. med.",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[47],{"name":48,"class":6},"University of Zurich","100507310",false,"NCT05885724","Novel Targetable BIOmarkers in ANorexia NervosA","Novel Targetable BIOmarkers in ANorexia NervosA - BIOANNA","BIOANNA","N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, non-exercising subtype\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 19-24.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Use of antibiotics within the last 31 days\n* Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed)\n* Any kind of severe chronic disease other than AN (e.g. active cancer disease)\n* Severe renal impairment (e.g. estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2) if resulting from another disease than AN\n* Known liver cirrhosis or other severe liver impairment if resulting from another disease than AN\n* Acute upper respiratory tract infection within the last 31 days\n* Uncontrolled dysthyroidism\n* Uncontrolled hypertension\n* Current pregnancy\u002Flactation or current treatment for in vitro fertilization\n* Inability to understand the study information, to sign the consent form and to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.",true,"ALL","18 Years","60 Years",{"count":61,"type":62},32,"ESTIMATED","OBSERVATIONAL","The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.",[66,67],"Anorexia Nervosa","Anorexia Nervosa Restricting Type",[69,70,71,72,73],"exercising subtype","non-exercising subtype","Neurofilament light chain","Glial fibrillary acidic protein","Growth Differentiation Factor-15","2024-12-06",{"date":76,"type":77},"2024-12-12","ACTUAL",{"date":79,"type":77},"2023-05-01",{"date":81,"type":62},"2025-04-30",{"name":5,"class":6},1]